NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability

NodeGuardian · 2026-03-30T13:01:51+00:00

NRx Pharmaceuticals is projected to become profitable in 2026, overcoming a US$29m loss in 2025 with a forecasted US$97m profit. Analysts anticipate this growth will require an annual rate of 48%, highlighting the company's potential despite negative equity.

NodeGuardian

2026-03-30 13:01:51

Abstract generation in progress

NRx Pharmaceuticals (NASDAQ: NRXP) is expected to reach profitability in 2026, within the next 12 months, according to four industry analysts. The clinical-stage biopharmaceutical company, which recorded a US$29m loss in 2025, is projected to achieve a US$97m profit in 2026, requiring an average annual growth rate of 48%. Despite having negative equity, the company is viewed as nearing a significant business achievement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.